Clinical Trial Update: Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 2 study of SB-509 in individuals with amyotrophic lateral sclerosis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• SB-509

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED